Biocoral, Inc. Announces Approval of its French Patent on the Process of Purification of Coral and its Use

NEW YORK, August 6 /PRNewswire-FirstCall/ -- Biocoral, Inc.(OTCBB-BCRA) announced today that recently the French Patent Office(Institut National de la Propriete Industrielle "INPI") approved andgranted a company patent called "Process of Purification of Coral and itsuse". The French Patent Office, after more then three years of examining ofthe company's application, granted the patent innovation to Bio HoldingsInternational Ltd., the Company's wholly owned subsidiary, under the patentnumber 03 14299. The Patent will expire in 2023. The INPI is a French Government Agency Patent Office, which contributesto the development of industry by securing and protecting the successfuland creative development of structures for patents, etc. The INPIrepresents France in the qualified international organizations and tocooperate to support the exchanges. Biocoral(R) Company's primary product is a natural coral "CarbonateCalcium" derived bone graft substitute and is used by surgeons andpractitioners because of its biocompatibility, resorbability, osseoconduction and safety. The original patent protecting the use of coral asbone substitute was filed in 1979 with its international extension in manycountries around the world by French government agency in charge ofscientific research (Centre National de la Recherche Scientifique "CNRS")before being taking over by the company subsidiary in the mid 1980's. For the past six years, the Company has collaborated with accreditedscientists as well as with a special laboratory located at one of mostprestigious European universities to develop a method of purification ofits raw material "coral," in order to remove the trace amounts (between0.016 to 0.026% depending upon the type of coral used) of amino acids whichwere present, without any change in chemical and crystalline structure ofthe coral. As a result of these efforts, the small percentage of amino acidcan now be removed from the Company raw material. Nasser Nassiri, the Chairman and Chief Executive Officer of Biocoral,Inc. commented, "The purification of our raw materials permits us toimprove their performance and to offer what we believe to be the onlynatural solely mineral bone substitute product in the world." Nasser Nassiri, further commented that, "The Company have filed apatent with an international extension for the method of purification ofits raw material and the final product issued using the method. Thegranting of this patent insures protection of the company's primary product"Biocoral(R)" until 2023. The Company believes that in the near future thecompany's patents covering this technology will receive approval in manyother countries where the company has already filed its applications." About Biocoral, Inc. Biocoral, Inc., a Delaware corporation, is an internationalbiomaterials "tissue-engineering" company specializing in the research anddevelopment of proprietary health care patented high technologies andbiomaterials. Biocoral(R), the Company's primary product, is a natural coral"carbonate Calcium" derived bone graft substitute and is used by surgeonsand practitioners because of its biocompatibility, resorbability, osseoconduction and safety. Certain chemical, physical and structuralcharacteristics of coral are very similar to that of human bone tissue.Biocoral(R) is derived from three particular species of coral naturallypresent in abundance. Biocoral(R) is primarily (more than 98%) comprised ofcalcium carbonate. Porous and resorbable, Biocoral(R) is prepared inmicrogranules as well as in engineered shapes according to specificindication. Due to its similarity to bone tissue, Biocoral(R) iscompatible, resorbed by the body as new bone growth invades the Biocoral(R)and is replaced by neoformed invasion. It is highly porous with numerousinterconnected channels which allow a total migration to the center of theimplant free of contamination risk. Because Biocoral(R) is resorbed, it canbe combined with antimicrobials, anticancer agents or other pharmaceuticalsfor slow release into bone tissue, resulting in an advantage overautologous bone grafts. The principal current alternative to Biocoral(R) isthe utilization of autologous (from the patient's own body) bone grafts.The use of autologous bone grafts requires the patient to undergo one ormore additional surgeries to harvest the bone graft material. This is notalways feasible due to the condition of the patient or othercontraindications, and must be shaped in a separate procedure to fit thegraft area. Through its subsidiaries, the Company researches, develops,manufactures and commercializes bone graft substitutes and other high techpatented biomaterials in a number of countries outside the United States.Biocoral, Inc. through its subsidiaries has developed the additional twelvetitles of patents for various applications and uses of its products, suchas a method of treating a disease associated with demineralization ormineralization bone defects ("osteoporosis remediation"), and combinationwith growth factor, among others. With these patents titles applications invarious countries in the European Community, Canada, the United States,Japan, Australia, and Switzerland, the Company owns more than 219 patentapplications around the world, and approximately 166 of these have thus farbeen granted by various countries' official government patent offices,including most European Community countries, Canada, Australia, Japan andin the United States by the US Department of Commerce Patent and TrademarkOffice. The information contained in this press release, including any "forwardlooking" statements within the meaning of section 27A of the Securities Actof 1933 and Section 21E of the Securities Exchange Act of 1934 containedherein, should be reviewed in conjunction with the Company's Annual Reporton Form 10-KSB and other publicly available information regarding theCompany, copies of which are available from the Company upon request. Suchpublicly available information sets forth many risks and uncertaintiesrelated to the Company's business and such statements, including risks anduncertainties related thereto that are unpredictable and outside of theinfluence and/or control of the Company. Contact: Biocoral, Inc. Nasser Nassiri +33-(0)1-47-57-9843